AKT1 and cancer: In addition, the development of drugs targeting the PI3K/AKT/mTOR or AMPK pathways for TNBC treatment described herein are a gradually developing field in which the efficacy and toxicity of new agents, in addition to their interactions with different cancer pathways, should be considered.